Results 181 to 190 of about 377,839 (219)

Two Doses of Measles Mumps Rubella (MMR) Vaccine

Pediatrics International, 1989
A schedule of two doses of measles mumps rubella vaccine (MMR) at an interval of six weeks was tried in children aged between 12 and 48 months. One hundred percent seroconversion was attained in the measles HI (hemagglutinin inhibition) test, rubella HI test, and mumps ELISA test in both groups of children who received NIH (National Institute of Health,
H, Kuno-Sakai, K, Ozaki, M, Kimura
openaire   +2 more sources

Response to measles-mumps-rubella vaccine in children on dialysis

Pediatric Nephrology, 1992
Ten children receiving maintenance dialysis were immunized with the standard dose of measles-mumps-rubella vaccine between 15 and 33 months of age. Immune responses to vaccination were determined using commercially available enzyme-linked immunosorbent assays for measles, mumps, and rubella viruses.
S L, Schulman, A, Deforest, B A, Kaiser, M S, Polinsky, H J, Baluarte   +4 more
openaire   +2 more sources

Is an Improved Measles-Mumps-Rubella Vaccine Necessary or Feasible?

Critical Reviews in Immunology, 2003
The measles-mumps-rubella (MMR) vaccine has been very effective in the elimination of disease and has high biosafety. However, it has been associated with several adverse effects and has recently caused controversy with regard to its possible association with inflammatory bowel disease and autism.
Gregory J, Atkins, S Louise, Cosby
openaire   +2 more sources

Egg Hypersensitivity and Measles-Mumps-Rubella Vaccine Administration

Pediatrics, 1991
Because reports have described egg-sensitive individuals in whom anaphylaxis developed after measles vaccination, current recommendations include delaying administration of egg-derived vaccines until skin testing can be performed. Specifically, the 1988 Red Book recommends skin testing via scratch, prick, or puncture with 1:10 dilution of the vaccine ...
S A, Beck, L W, Williams, M A, Shirrell, A W, Burks   +3 more
openaire   +2 more sources

A combination vaccine against measles, mumps, rubella and varicella

Drugs of Today, 2008
A new combination vaccine against measles, mumps, rubella and varicella (MMRV) from GlaxoSmithKline Biologicals has recently been approved in Europe. It combines the components from two well-established, live, attenuated vaccines against measles, mumps and rubella.
Markus, Knuf, Jörg, Faber, Immanuel, Barth, Pirmin, Habermehl   +3 more
openaire   +2 more sources

Combined Live Measles, Mumps, Rubella Vaccine

American Journal of Diseases of Children, 1971
A combined live attenuated measles, mumps, rubella vaccine was administered to 40 susceptible (seronegative) infants, 12 to 26 months of age. The antibody responses to the three viruses were excellent and the vaccine was well tolerated.
S, Krugman, G, Muriel, V J, Fontana
openaire   +2 more sources

Neurologic Disorders After Measles-Mumps-Rubella Vaccination

Pediatrics, 2002
Objective. The possibility of adverse neurologic events has fueled much concern about the safety of measles-mumps-rubella (MMR) vaccinations. The available evidence concerning several of the postulated complications is controversial. The aim of this study was to assess whether an association prevails between MMR vaccination and encephalitis, aseptic ...
Annamari, Mäkelä, J Pekka, Nuorti, Heikki, Peltola   +2 more
openaire   +2 more sources

A new combination vaccine for measles, mumps, rubella and varicella

Drugs of Today, 2006
ProQuad is a recently approved combination vaccine for simultaneous vaccination against measles, mumps, rubella and varicella in children aged 12 months to 12 years. It combines two well-established vaccines: Measles, Mumps, Rubella Virus Vaccine Live (M-M-R II) and Varicella Virus Vaccine Live (Varivax with higher varicella-zoster titer).
openaire   +2 more sources

On-line Documentation of Measles-Mumps-Rubella Vaccine Inoculation

Archives of Pediatrics & Adolescent Medicine, 1985
Sir .—In 1984, at the time of a measles outbreak among students at Dartmouth College, Hanover, NH, an audit of 4,903 student health records revealed that 59.6% lacked adequate documentation of measles immunity. The overall attack rate among the students was 0.7% (varying from 3.2% to 0.6%) during the outbreak, yet an extensive vaccination program was ...
openaire   +2 more sources

Measles Mumps Rubella (MMR) Vaccine in Japan

Pediatrics International, 1988
H, Kuno-Sakai, M, Kimura
openaire   +2 more sources